References
- Barraud C, Desguerr I, Barnerias C, et al. Clinical features and evolution of juvenile myasthenia gravis in a French cohort. MuscleNerve. 2018;57:603–609.
- Huang S, Wang W, Chi L. Feasibility of up-regulating CD4 + CD25+ Tregs by IFN-Υ in myasthenia gravis patients. BMC Neurol. 2015;15(1):163.
- Molin CJ, Westerberg E, Punga AR. Profile of upregulated inflammatory proteins in sera of myasthenia gravis patients. Sci Rep. 2017;7:39716.
- Uzawa A, Kanai T, Kawaguchi N, et al. Changes in inflammatorycytokine networks in myasthenia gravis. Sci Rep. 2016;6(1):25886–258990.
- Luo J, Lindstrom J. AChR-specific immunosuppressive therapy of myasthenia gravis. Bioochem Pharmacol. 2015;97(4):609–619.
- Jing F, Yang F, Cui F, et al. Rapamycin alleviates inflammation and muscle weakness, while altering the Treg/Th17 balance in a rat model of myasthenia gravis. Biosci Rep. 2017;37(4):1–10.
- Shahgah AG, Fattahi E, Shahneh FZ. Interleukin-17 in human inflammatory disease. Postepy Dermatol Altrgol. 2014;31(4):256–261.
- Chen G, Zhu L, Yang Y, et al. Prognostic role of neutrophil-to-lymphocyte ratio inovarian cancer: a meta-analysis. Technol Cancer Treatment. 2018;1:17.
- Kaushik R, Gupta M, Sharma M, et al. Diagnostic and prognostic role of neutrophil-to-lymphocyte ratio in early and late phase of sepsis. Indian J Crit Care Med. 2018;22(9):660–663.
- Yang DH, Qian MZ, Wei MM, et al. The correlation of neutrophil-to-lymphocyte ratio with the presence and activity of myasthenia gravis. Oncotarget. 2017;8(44):76099–76107.
- Jaretzki A, 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, et al. Myasthenia gravis:recommendations for clinical research standards. Task Force of the Medical Scientific Adisory Board of the Myasthenia GravisFoundation of America. Ann Thorac Surg. 2000;70(1):327–334.
- Yang D, Weng Y, Lin H, et al. Serum uric levels in patients with myasthenia gravis are inversely correlated wirh disability. NeuroReport. 2016;27(5):301–305.
- Uzawa A, Kawaguchi N, Kanai T, et al. Increased ser-um peroxiredoxin 5 levels in myasthenia gravis. J Neuroimmunol. 2015;287:16–18.
- Uzawa A, Kawaguchi N, Kanai T, et al. Serum high mobilitygroup box 1 is upregulated in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2015;86(6):695–697.
- Gihus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14:1023–1036.
- Uzawa A, Kawaguchi N, Himuro K, et al. Serum cytokine and chemokine profiles in patients with myasthenia gravis. Clin Exp Immunol. 2014;176(2):232–237.
- Weng YY, Yang DH, Qian MZ, Wei MM, et al. Low serum albumin concentrations are associated with disease severity in patients with myasthenia gravis. Medicine. 2016;95:39–44.
- Lee YS, Nam HS, Lim JH, et al. Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer. BMC Cancer. 2017;17(1):557.
- Zhang Y, Lu JJ, Du YP, et al. Prognostic value of ne-utrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer. Medicine. 2018;97:12.
- Guan YZ, Gui LY, Li YF, et al. Tumor necrosis factor-α polymorphism and secretion in myasthenia gravis. Clin Med Sci. 2005;20(2):104–107.
- Lee JS, Joo IS, Seok JI. Widely varying TNF-alpha levels in patients with myasthenia gravis. Neurol Sci. 2009;30(3):259–262.
- Aricha R, Mizrachi K, Fuchs S, et al. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J Autoimmun. 2011;36(2):135–141.
- Cao Y, Amezquita RA, Kleinstein SH, et al. Autoreative T cells from patients with myasthenia gravis are characterized by elevated IL-17, IFN-Y, and GM-CSF and diminished IL-10 production. JI. 2016;196(5):2075–2084.
- Kusner LL, Kaminski HJ. The role of complement in experimental autoimm-une myasthenia gravis. Ann N Y Acad Sci. 2012;1274(1):127–132.
- Truffault F, de Montpreville V, Eymard BS, et al. Thymic germinal centers and corticosteroids in myasthenia gravis:an immunopathological study in 1035 cases and a critical review. Clinic Rev Allerg Immunol. 2017;52(1):108–124.
- Cavalcante P, Cufi P, Mantegazza R, et al. Etiology of myasthenia gravis: innate immunity signature in pathological thymus. Autoimmun Rev. 2013;12(9):863–874.
- Fuhua P, Xuhui D, Zhiyang Z, et al. Antioxidiant status of bilirubin and uric acid in Patient with myasthenia gravis. Neuroimmunomodulation. 2012;19(1):43–49.